Design, Synthesis, and Biological Evaluation of Evodiamine Derivatives as Antibody–Drug Conjugate Payloads

= 8.369 and 4.899 nm in HCC1954 and NCI-N87 cells, respectively) compared to the control group Ab-LC08-SN38. This study is the first application of evodiamine derivatives as TOPO I/II dual inhibitors in the ADC field, which not only provides a new strategy for the development of ADC payloads, but also enriches the innovative application of natural product small molecules in tumor-targeted therapy.